gptkbp:instance_of
|
gptkb:drug
|
gptkbp:activities
|
inhibitor of FL T3 kinase
|
gptkbp:appointed_by
|
oral tablet
|
gptkbp:approves
|
gptkb:2014
gptkb:United_States
|
gptkbp:brand
|
gptkb:Pralsetinib
|
gptkbp:class
|
gptkb:Cloud_Computing_Service
|
gptkbp:clinical_trial
|
gptkb:Ariad_Pharmaceuticals
gptkb:Europe
gptkb:Asia
gptkb:United_States
Phase 1
Phase 3
|
gptkbp:composed_of
|
gptkb:chemical_compound
|
gptkbp:contraindication
|
severe renal impairment
severe liver impairment
hypersensitivity to crenolanib
|
gptkbp:date
|
2015-01-15
|
gptkbp:discovered_by
|
gptkb:Ariad_Pharmaceuticals
|
gptkbp:dissolved
|
soluble in DMSO
slightly soluble in water
|
gptkbp:healthcare
|
2014-10-01
|
https://www.w3.org/2000/01/rdf-schema#label
|
Crenolanib
|
gptkbp:ingredients
|
C22 H24 Cl N5 O2 S
|
gptkbp:interacts_with
|
CY P3 A4 inducers
CY P3 A4 inhibitors
QT prolonging agents
|
gptkbp:invention
|
patented
|
gptkbp:is_atype_of
|
L01 XX
|
gptkbp:is_used_for
|
treatment of acute myeloid leukemia
|
gptkbp:manager
|
oral
|
gptkbp:marketed_as
|
gptkb:Ariad_Pharmaceuticals
|
gptkbp:pharmacokinetics
|
oral bioavailability
FL T3 inhibition
|
gptkbp:population
|
adults with AML
|
gptkbp:produced_by
|
clinical trials
|
gptkbp:project
|
Phase 2
|
gptkbp:provides_information_on
|
daily dosing
|
gptkbp:research_areas
|
various cancer research centers
|
gptkbp:research_focus
|
oncology
|
gptkbp:side_effect
|
gptkb:fandom
fatigue
nausea
diarrhea
liver enzyme elevation
thrombocytopenia
infection risk
cardiac arrhythmias
bleeding complications
|
gptkbp:targets
|
gptkb:healthcare_organization
FL T3 receptor
|
gptkbp:treatment
|
improved survival rates
reduced relapse rates
increased complete response rates
|
gptkbp:type_of
|
1000370-80-0
|
gptkbp:weight
|
429.97 g/mol
|
gptkbp:bfsParent
|
gptkb:Genzyme_Genetics
|
gptkbp:bfsLayer
|
5
|